Cognition Therapeutics Formally Advances DLB Drug to Registrational Study; FDA Minutes Expected June
CGTX has more than doubled off its 52-week low of $0.25 on elevated volume (1.9× avg).
Summary
Cognition Therapeutics is formally advancing its zervimesine candidate into a registrational program for Dementia with Lewy Bodies (DLB) psychosis, following a positive FDA meeting announced on May 21st. The company filed a Regulation FD presentation outlining plans for a 9-month randomized registrational study, based on compelling Phase 2 data. This is a significant step for the drug's path to market. The company also confirmed its cash runway extends into Q2 2027. Traders should look for the release of FDA meeting minutes, expected in June, for further details on the program's progression.
At the time of this announcement, CGTX was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.1M. The 52-week trading range was $0.25 to $3.83. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.